Zoloft Label Will Show Increased Heart Defect Risks in Children
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. It appears we are about to see a long delayed and much-needed warning added to the Zoloft label. Pfizer Inc. is in talks with the U.S. Food and Drug Administration to update the label on its antidepressant Zoloft to finally and
Read MoreFDA Raises New Problems for Invokana and Invokamet
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. The FDA issued today a new safety communication regarding the already controversial drugs Invokana and Invokamet (canagliflozin) highlighting safety concerns over bone breaks and reduced bone density. The safety communication can be read below: Drug Safety Communication – New Information on
Read More
Onglyza and the Risks of Heart Failure and Pancreatic Cancer
Where you or a loved one harmed by Onglyza? This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm Researchers associate this Type 2 diabetes drug with some very serious complications. These include heart failure, pancreatitis, and pancreatic cancer. The national pharmaceutical practice group of The Michael Brady Lynch Firm is
Read More
The Michael Brady Lynch Firm Files Zofran Cleft Lip Lawsuit
For Immediate Release: August 20, 2015 Today, the nation mass tort litigation practice of The Michael Brady Lynch Firm filed a new lawsuit on behalf of a Massachusetts family against GlaxoSmithKline LLC in the United States District Court for Massachusetts. The family asserts that GSK’s anti-nausea prescription drug Zofran caused their daughter to be born
Read MoreJPML Approves MDL of Bard IVC Cases
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. The case against the safety and effectiveness of the IVC filter just moved up a notch. The Judicial Panel on Multidistrict Litigation announced that all pending IVC Filter cases against C.R. Bard, Inc. and Bard Peripheral Vascular will be consolidated and
Read MoreThe Dangers of Heart Failure Associated with Onglyza
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. When Onglyza (saxagliptin) arrived on the marker in 2009, it was seen as a new frontier in maintaining blood sugar levels in type 2 diabetics. The excitement faded when the drug was linked to heart failure and other serious complications. These
Read MoreADHD Medication Daytrana Linked to Permanent Skin Discoloration
This Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. Another ADHD medication is coming under scrutiny for severe and permanent sides effects. On June 24, 2015, the Food and Drug Administration warned that Daytrana, a pharmaceutical patch approved to treat attention deficit hyperactivity disorder (ADHD), can cause permanent skin discoloration. The
Read MoreAttorney Michael Brady Lynch to Lecture at AAJ Convention in Montreal
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. It is new pleasure to announced that I have been selected to serve on the faculty of the upcoming AAJ Annual Convention educational seminar in Montreal entitled “Everything You Need to Know About Mass Torts (But Were Afraid to Ask)”, on Friday, July
Read MoreInvokana Linked to Ketoacidosis, Heart Attack and Renal Failure
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm. The popular diabetes drug Invokana (Invokamet) has raised grave concerns over safety due to links between the use of the medication and kidney damage, myocardial infarction (heart attacks), other cardiovascular issues and ketoacidosis. National Invokana (Invokamet) lawsuits allege that the manufacturers
Read MoreMichael Brady Lynch to Lecture at Barry University School of Law
This is Michael Brady Lynch, lead trial attorney at The Michael Brady Lynch Firm. It is my pleasure to announce that I have been invited as a guest lecturer at Barry University School of Law’s Clinical Placement Program. Barry University School of Law’s Clinical Placement Program, in conjunction with the Florida Supreme Court, permits primarily third-year
Read More